NASDAQ · JBIO
Jade Biosciences, Inc.
$14.24-$0.35 (-2.4%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.14% below the high.
Loading market information…
NASDAQ · PLYX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Polaryx Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Polaryx Therapeutics, Inc. Common Stock’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Polaryx Therapeutics, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $6.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.24-$0.35 (-2.4%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.14% below the high.
$14.07+$0.57 (+4.22%)
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
$11.31+$0.38 (+3.43%)
Lyell Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.88% below the high.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$2.09-$0.04 (-1.88%)
Foghorn Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.54% below the high.
$16.54+$0.80 (+5.08%)
Pelthos Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.89% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$2.13+$0.12 (+5.97%)
Kalaris Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 82.07% below the high.
